Atlas Trials

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Clinical trial NCT00230282 · COMPLETED

Trial details

NCT number
NCT00230282
Sponsor
Steven E. Coutre
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
LeukemiaB-cell LeukemiaChronic LeukemiaChronic Lymphocytic Leukemia (CLL)
Start date
2004-07-01
Primary completion
2010-12-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.